Frost & Sullivan’s to recognize Icon Genetics with the 2012 European Technology Innovation Award.

Icon Genet­ics GmbH (ICON), Munich/Halle, Ger­many, a plant biotech­nol­o­gy com­pa­ny, has announced that the Com­pa­ny has been award­ed a pres­ti­gious Frost & Sul­li­van Euro­pean Tech­nol­o­gy Inno­va­tion Award.
For the Tech­nol­o­gy Inno­va­tion Award, the fol­low­ing cri­te­ria were used to bench­mark Icon Genet­ics’ per­for­mance against key com­peti­tors: unique­ness of the tech­nol­o­gy; impact on new products/applications; impact on func­tion­al­i­ty; impact on cus­tomer val­ue, and rel­e­vance of the inno­va­tion to the indus­try. To sup­port its eval­u­a­tion of best prac­tices across mul­ti­ple busi­ness per­for­mance cat­e­gories, Frost & Sul­li­van employs a cus­tomized Deci­sion Sup­port Matrix (DSM), an ana­lyt­i­cal tool that com­pares com­pa­nies’ per­for­mance rel­a­tive to each oth­er with an inte­gra­tion of quan­ti­ta­tive and qual­i­ta­tive met­rics. The DSM fol­lows a 10-point scale that allows for nuances in per­for­mance eval­u­a­tion. The ana­lysts of Frost & Sul­li­van have rat­ed Icon Genet­ics’ tech­nol­o­gy as ‘excel­lent’ and ‘the best in its class’ with an over­all rat­ing of 9.3.

The report con­cludes: ”Icon Genet­ics has estab­lished itself as a leader in the devel­op­ment of a suite of tools for plant-based recom­bi­nant expres­sion. They have con­duct­ed sys­tem­at­ic stud­ies of all routes for express­ing recom­bi­nant pro­teins in plants and they have devel­oped opti­mized tool sets for each route. Their busi­ness mod­el is cus­tomer-cen­tric as they do not mere­ly have a licens­ing propo­si­tion, but also train their cus­tomers to use their mag­nI­CON® and oth­er sys­tems in a joint effort of research and devel­op­ment. They also have their own cGMP-com­pli­ant facil­i­ty, enabling them to devel­op and man­u­fac­ture in-house prod­ucts. The effi­cien­cy and yield of recom­bi­nant pro­tein from plants is the high­est in the indus­try and they have expand­ed their appli­ca­tion endeav­ors to include non-phar­ma­ceu­ti­cal uses of recom­bi­nant pro­teins in antimi­cro­bials and antivi­rals through Nomad Bio­sciences, its par­ent com­pa­ny. Based on Frost & Sullivan’s inde­pen­dent analy­sis of Recom­bi­nant Expres­sion Sys­tems, Icon Genet­ics is rec­og­nized with the 2012 Euro­pean Tech­nol­o­gy Inno­va­tion Award.”

About ICON:
Icon Genet­ics is cur­rent­ly a whol­ly owned sub­sidiary of Nomad Bio­science GmbH, Munich, Ger­many. The Com­pa­ny dis­cov­ers and devel­ops new bio­phar­ma­ceu­ti­cals and high-val­ue pro­tein prod­ucts using green plants as pro­duc­tion hosts. ICON offers new plant man­u­fac­tur­ing tech­nolo­gies which address speed, yield, pre­ci­sion, expres­sion con­trol and safe­ty of prod­uct man­u­fac­tur­ing in plants. ICON oper­ates its own cGMP-com­pli­ant man­u­fac­tur­ing facil­i­ty in Halle, Ger­many. ICON’s own pipeline includes sev­er­al ‘bio­bet­ter’ anti-can­cer anti­bod­ies (pre-clin­i­cal stage).

About Frost & Sul­li­van:
Frost & Sul­li­van, the Growth Part­ner­ship Com­pa­ny, enables clients to accel­er­ate growth and achieve best-in-class posi­tions in growth, inno­va­tion, and lead­er­ship. The company’s Growth Part­ner­ship Ser­vice pro­vides the CEO and the CEO’s Growth Team with dis­ci­plined research and best-prac­tice mod­els to dri­ve the gen­er­a­tion, eval­u­a­tion, and imple­men­ta­tion of pow­er­ful growth strate­gies. Frost & Sul­li­van lever­ages 50 years of expe­ri­ence in part­ner­ing with Glob­al 1,000 com­pa­nies, emerg­ing busi­ness­es and the invest­ment com­mu­ni­ty from more than 40 offices on six con­ti­nents. To learn more, please vis­it